SUNRISE: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Previously Treated Stage IIIb/IV Non-Squamous Non Small-Cell Lung Cancer

Trial Profile

SUNRISE: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Previously Treated Stage IIIb/IV Non-Squamous Non Small-Cell Lung Cancer

Discontinued
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Bavituximab (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms SUNRISE
  • Sponsors Peregrine Pharmaceuticals
  • Most Recent Events

    • 12 Sep 2017 Results of exploratory analysis asssessing bavituximab + docetaxel versus docetaxel monotherapy, as second-line treatment, in patients with non-squamous cell advanced or metastatic non-small cell lung cancer who have progressed after standard first-line therapy, were presented at the 42nd European Society for Medical Oncology Congress.
    • 05 Jun 2017 Results from this trial published in a Peregrine Pharmaceuticals Media Release.
    • 02 Jun 2017 Results of a retrospective biomarker exploratory analyses in a subset of SUNRISE patients, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top